III Capital Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

III Capital Management’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-18,900	Closed	-$1.68M	–	170
2023 Q2	$1.64M	Buy	+18,900	New	+$1.78M	0.1%	87
2020 Q1	–	Sell	-10,000	Closed	-$862K	–	60
2019 Q4	$845K	Buy	+10,000	New	+$755K	0.43%	32

Other funds holding BMRN

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

III Capital Management's BMRN Position: Q3 2023 in Review

III Capital Management sold out of BioMarin Pharmaceuticals (BMRN) in Q3 2023, closing a stake of 18,900 shares — an estimated $1.68M sold.

III Capital Management first reported a position in BMRN in Q4 2019 and held it in 2 quarters. The position peaked at $1.64M in Q2 2023. 519 funds tracked by Wall St. Rank hold BMRN as of Q3 2023.

III Capital Management reported no remaining BioMarin Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
III Capital Management sold 18,900 BioMarin Pharmaceuticals shares in Q3 2023, an estimated $1.68M.
III Capital Management first reported a position in BioMarin Pharmaceuticals in Q4 2019 and held it in 2 quarters.
III Capital Management's BioMarin Pharmaceuticals position peaked at $1.64M in Q2 2023.
519 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q3 2023.

Based on III Capital Management's 13F filing for Q3 2023, filed 14 Nov 2023.